Hariprasad Vankayalapati, M. Pharm., PhD. Chief Scientific Officer & Founder
Hari is a founder of Arrien Pharmaceuticals, serves as Chief Scientific Officer and SAB Member of the Company. Hari developed the empirical-driven FIELDS technology, successfully translated the FIELDS in to early discovery pipeline of targeted therapeutics development for Cancer, Autoimmune and CNS/Neurodegenerative diseases. He is currently serving as Associate Prof. at TGen supporting drug discovery programs for cancer immunotherapeutics. He was Asst. Prof./Chief Scientist at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute (HCI) and School of Medicine of University of Utah. His presence at HCI lead to the discovery of two agents (HCI-2577/SP-2577, HCI-2084/TP-0903) currently in Phase 1 clinical trials. From 2006-2009, Hari was Chief Scientist at SuperGen, Inc., (now Astex/Otsuka Pharmaceuticals). From 2003-2006 he was a Director of Medicinal Chemistry for early discovery/development activities and was key in creating three clinical agents; MP-470/Amuvatinib, SGI-1776 and SGI-110/Guadecitabine, several pre-clinical candidates, CLIMB technology and co-founded Montigen Pharmaceuticals with an initial Series B of 5 million. In year 2006 Montigen was acquired by SuperGen for 40 million where Hari played a key role in bringing science/technology in this deal transaction.
He is an author of more than 70 publications, presentations, and an inventor of several issued/published US/WO patents. Hari received Ph.D. and M. Pharm degrees in Medicinal Chemistry from Institute of Chemical Technology (formally UDCT) of University of Mumbai and University of Karnatak in India. He completed his Postdoctoral training in Organic Chemistry from University of Sunderland in England and Medicinal Chemistry from University of Arizona Cancer Center with Prof. Laurence H. Hurley.
Rajendra P. Appalaneni, B. Pharm Chairman & Founder
Rajendra Appalaneni is a founder of Arrien Pharmaceuticals and currently serving as Chairman and Board of Directors of the company. Rajendra is also serving as Chairman and President of Appco Pharma, a generic Pharmaceutical manufacturing company located in NJ and was a Co-founder of Alveus Pharmaceuticals.
Roy J Wu, M.B.A. Vice President of Business Development
Roy J. Wu joined Arrien Pharma in August of 2016 as the Vice President of Business Development and will lead the business development and licensing activities for Arrien Pharma's development programs. Prior to joining Arrien Pharma, Mr. Wu served as Senior Vice President for Business and Corporate development at NovaBay Pharmaceuticals from July 2009 through March 2016 where he was responsible for business development and licensing activities, including search, evaluation, and contract negotiations for all in- and out-license transactions, alliance management and assisting in corporate financing activities. While at NovaBay, Mr. Wu successfully completed multiple license agreements and distribution agreements with US as well as with International Pharma companies.
From 2001 to 2009, Mr. Wu was the Vice President of Business Development at Genelabs Technologies, where he completed licensing agreements and research collaborations with companies including Novartis, Gilead Sciences, Tanabe Seiyaku and Affymetrix. Mr. Wu also served as Vice President of Kissei Pharma USA Inc., from 1997 to 2001, where he managed clinical development, regulatory affairs and business development departments. Prior to Kissei Pharma USA. Mr. Wu served as Director of Business Development at Quintiles-BRI from 1995 to 1997 and for 16 years at Syntex Corporation where he started as a chemist and advanced his professional career until he became Director R&D Planning and Management, Japan. Mr. Wu received an M.B.A. in international finance from the University of San Francisco, School of Business and a B.A. in biology from the University of San Francisco.